Economic burden of drug-induced anaphylaxis: what can we do better?

Purpose of review This systematic review evaluates published data related to the economic burden of drug-induced anaphylaxis (DIA) to understand preventive cost saving measures that could reduce the burden of these conditions. Recent findings Although DIA has a relevant societal impact, there are limited and heterogenous available data related to its cost. Direct costs related to the management of acute phase of DIA was estimated by $529.6 to $3125, depending on the number of emergency room visits/hospitalizations, emergency kits and transports in ambulance. Direct costs of investigations of DIA varied from $288 to $2292.95 and the desensitization was estimated by $6796. Main variables for this were: personnel, allergy screening procedures, medical consumables and space cost. The mean indirect cost was based on a mean absenteeism of 3 days per DIA corresponding to $381.2. More than reviewing the published data, we were able to identify variables that, if correctly managed, can reduce the economic burden of DIA, such as adjusting the timing of referral and etiological diagnosis, identification of potential risk and/or co-factors, correct written recommendations to patients. The evidence presented highlights the need of optimization of healthcare patients to patients suffering from DIA.

Automated summary

This systematic review evaluates the economic burden of drug-induced anaphylaxis (DIA) and proposes cost-saving measures to reduce the burden. Although DIA has a significant societal impact, there is limited and heterogeneous data on its cost. The study found that direct costs include the management and investigation expenses of DIA, while indirect costs include economic losses due to absenteeism. By appropriately managing certain variables, the economic burden of DIA can be reduced.